secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001628280-24-012365
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci Q4 net loss $23.5M; initiates IND-enabling for ABS-101; AstraZeneca deal up to $247M
--------------------------------------------------------------------------------

- FY23 net loss $110.6M, revenue $5.7M flat YoY; Q4 net loss $23.5M.
- Initiated IND-enabling for ABS-101 (anti-TL1A); IND expected Q1 2025.
- Signed AstraZeneca collaboration for up to $247M in milestones plus royalties.
- Raised $86.4M in common stock offering; cash $97.7M at Dec 31; runway into H1 2027.
- Appointed Sir Menelas Pangalos to Board and co-chair of Scientific Advisory Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828024012365/0001628280-24-012365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828024012365/absc-20240321.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-012365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer